Company intelligence / Profile preview

PLx Pharma Inc.

Sparta, New Jersey, United Statessec.gov ↗

Ownership: Private
Development stage: NDA

Overview

PLx Pharma developed the patent-protected PLxGuard™ drug delivery platform designed to release active pharmaceutical ingredients in the duodenum rather than the stomach, aiming to improve absorption and reduce gastrointestinal side effects. Their lead product was a GI-safer aspirin formulation intended for cardiovascular disease prevention. The company also had a clinical-stage ibuprofen program. Despite promising technology and clinical validation, the company entered bankruptcy after raising over $40 million in funding.

Therapeutic areas: CardiovascularRheumatology
Modalities: Small molecules (focus on oral NSAIDs such as aspirin and ibuprofen)
Industry: Biotech

Drug pipeline

5 assets

pl-2200

Approved

4 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on PLx Pharma Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PLx Pharma Inc..

Explore the full profile